Marshall Wace
RYTM icon

Marshall Wace’s Rhythm Pharmaceuticals RYTM Stock Holding History

Marshall Wace’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$908K Sell
8,174
-1,454
-15% -$131K ﹤0.01% 2246
2026
Q1 		$837K Buy
+9,628
New +$936K ﹤0.01% 2216
2025
Q4 		– Sell
-171,834
Closed -$17.4M – 3415
2025
Q3 		$17.4M Sell
171,834
-204,408
-54% -$19M 0.02% 714
2025
Q2 		$23.8M Sell
376,242
-158,861
-30% -$9.73M 0.03% 524
2025
Q1 		$28.3M Sell
535,103
-157,700
-23% -$8.75M 0.04% 423
2024
Q4 		$38.8M Buy
692,803
+286,188
+70% +$15.8M 0.05% 342
2024
Q3 		$21.3M Buy
406,615
+299,806
+281% +$14.4M 0.03% 491
2024
Q2 		$4.39M Buy
106,809
+87,059
+441% +$3.48M 0.01% 1052
2024
Q1 		$856K Buy
+19,750
New +$864K ﹤0.01% 1716
2023
Q4 		– Sell
-34,494
Closed -$791K – 2556
2023
Q3 		$791K Sell
34,494
-1,877
-5% -$42K ﹤0.01% 1573
2023
Q2 		$600K Sell
36,371
-57,475
-61% -$1.04M ﹤0.01% 1917
2023
Q1 		$1.67M Buy
93,846
+72,563
+341% +$1.82M ﹤0.01% 1549
2022
Q4 		$620K Buy
+21,283
New +$547K ﹤0.01% 2289
2021
Q2 		– Sell
-178,757
Closed -$3.8M – 3028
2021
Q1 		$3.8M Buy
178,757
+159,599
+833% +$4.63M 0.02% 992
2020
Q4 		$570K Sell
19,158
-9,034
-32% -$230K ﹤0.01% 1415
2020
Q3 		$611K Buy
28,192
+17,935
+175% +$411K ﹤0.01% 1177
2020
Q2 		$229K Buy
+10,257
New +$200K ﹤0.01% 1388
2019
Q4 		– Sell
-2,298
Closed -$50K – 2013
2019
Q3 		$50K Buy
+2,298
New +$49.3K ﹤0.01% 1492
2019
Q2 		– Sell
-14,715
Closed -$403K – 1767
2019
Q1 		$403K Buy
14,715
+12,417
+540% +$357K ﹤0.01% 1196
2018
Q4 		$62K Buy
+2,298
New +$63.5K ﹤0.01% 1427

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marshall Wace's RYTM Position: Q2 2026 in Review

Marshall Wace reduced its Rhythm Pharmaceuticals (RYTM) stake by 15% in Q2 2026, selling an estimated $131K and leaving 8,174 shares worth $908K. The position accounts for ﹤0.01% of the portfolio, ranked #2246.

Marshall Wace first reported a position in RYTM in Q4 2018 and has held it in 20 quarters since. The position peaked at $38.8M in Q4 2024. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Marshall Wace held 8,174 shares of Rhythm Pharmaceuticals worth $908K as of Q2 2026.
  • Marshall Wace sold 1,454 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $131K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2246 holding.
  • Marshall Wace first reported a position in Rhythm Pharmaceuticals in Q4 2018 and has held it in 20 quarters since.
  • Marshall Wace's Rhythm Pharmaceuticals position peaked at $38.8M in Q4 2024.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.